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Urgency is the cornerstone symptomof overactive bladder (OAB) syndrome, which is associatedwith reduced health-related quality
of life (HRQoL) and affects patients with different profiles. We report here three clinical pictures of OAB: a male patient with mixed
lower urinary tract symptoms (LUTS), a youngwomanwith comorbidities, and an elderlywomanwithmixed urinary incontinence.
The aim is to analyze the specificities of these real cases, to discuss what would be the most appropriate management, and how
treatment with fesoterodine, an antimuscarinic agent with key pharmacological properties, might meet the patients’ expectations.
Relevant and constructive messages are drawn: urgency, the cornerstone symptom, should be given special attention; fesoterodine
is effective and well tolerated in the elderly; before switching to another medication consider increasing the dosage of fesoterodine;
the major goal of initial therapy is to meet patient expectations; and involving the patient in the treatment plan increases her/his
adherence.
1. Introduction
Overactive bladder (OAB) syndrome covers several symp-
toms: urinary urgency, which is the cornerstone symptom
[1], usually associated with urinary frequency and nocturia,
and with or without urgency urinary incontinence (UUI).
The term of OAB applies if there is no proven infection
or other obvious pathology [2, 3]. OAB is correlated with
reduced health-related quality of life (HRQoL) and affects
patients with different profiles. Patients with OAB may be
children, premenopausal and postmenopausal women, men
with benign prostate hypertrophy (BPH), or frail elderly
patients. Their symptoms are known to be bothersome and
treatable [4]. Patients have different needs and also specific
expectations, which are sometimes challenging for the physi-
cian in charge, but must be set right. Gynecologists often care
for women with urinary symptoms of urgency and frequency,
but they may not always be recognized as OAB.
We report three main clinical pictures of OAB: a
male patient presenting with lower urinary tract symptoms
(LUTS), including urgency; a young woman with comorbidi-
ties; and an elderly woman with mixed urinary incontinence,
with the aim of highlighting the specific features of these
real-life cases, discussing the most appropriate management,
and assessing how fesoterodine treatment may meet these
patients’ expectations.
Fesoterodine possesses four key pharmacological proper-
ties [5–8]. Firstly, it is immediately and completely metab-
olized into its active form, the 5-hydroxymethyl tolterodine
(5-HMT) by ubiquitous plasma esterases. Thus, its activation
is not affected by genetic variability in hepatic enzymes [5].
This may explain the dose-response relationship observed
clinically. Secondly, fesoterodine has a very low risk of
crossing the blood brain barrier, and has no significant
effect on cognitive function, which has been confirmed
in clinical trials [6]. Thirdly, it possesses a well-balanced
affinity ratio on detrusor M2 and M3 receptors, which
explains its further actions on contraction and on relaxation,
increasing the bladder capacity [9]. Finally, the 7–9-hour half-
life of fesoterodine allows a single daily dose to be taken,
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avoiding the risk of accumulation of the active ingredient
[10].
As mentioned in the product specifications (Toviaz
SPCs) [11], two doses, 4 and 8 mg, are available. The
recommended starting dose is 4 mg once daily. Fesoterodine
8mg has proven its superiority compared to 4mg in reducing
UUI episodes in a head-to-head comparison inOABpatients;
the 8mgdosewas alsomore effective in controlling frequency
and nocturia [12].
2. First Case: Mr. LUTS and OAB
The first case reported the history of “Mr. LUTS and OAB”,
who is 72 years of age, has had LUTS for five years, has a
weak and variable stream, complains of painful micturition
if he waits too long between micturitions, and also of
frequency, urgency, and nocturia. There were no signs of
bladder outlet obstruction or other identified etiology. He
has been diagnosed with hypertension and type 2 diabetes.
He takes several medications: a beta-blocker, a selective
AT1-subtype angiotensin II receptor antagonist, a calcium
antagonist, and an oral biguanide antihyperglycemic agent.
His International Prostate Symptom Score (IPSS) is 15, and
the QoL question was scored as 4. Digital rectal examination
revealed a slight increase in the size of the prostate, with
an estimated volume of 50–60 ml. He has been offered
transurethral resection of the prostate (TURP) but declined.
The European Association of Urology (EAU) guidelines [16]
state that prostate-specific antigen (PSA) should be tested if
a diagnosis of prostate cancer will change management or if
it assists in the treatment and/or decision-making process;
his PSA was within the normal range, at 2.6 ng/ml. His
IPSS value for storage symptoms was higher than his score
for voiding symptoms. He was prescribed an alpha blocker
(tamsulosin) as a first-line treatment. Six weeks later, at the
next visit, he reported a slight improvement in frequency and
stream, with no change in nocturia or urgency, and some
ongoing rareUUI episodes and dysuria.HisQoL score, which
was linked to urgency, was not improved. Uroflowmetry was
performed and showed a Qmax of 11 ml/s, a voiding volume
(VV) of 140 ml, and a postvoiding residual (PVR) of 45 ml.
Transrectal ultrasound confirmed an enlarged prostate (68
ml).
“Mr. LUTS and OAB” was offered a combination treat-
ment with tamsulosin and dutasteride to try to control his
symptoms and reduce the weight of his prostate. Three
months later, he came back for a follow-up visit and declared
he had stopped dutasteride after two weeks because of
erectile dysfunction. Hewas still complaining of nocturia and
urgency. The control of PVR indicated a residue lower than
100 ml.
A frequency-volume chart (FVC) that collects the time
and volume of micturitions can be a useful tool to obtain a
real assessment of nocturia. Van Haarst et al. [17] analyzed
two different ways of measuring nocturia and showed that in
50% of the patients the IPSS nocturia score was found to be
higher than nocturia calculated from the FVC, indicating that
the IPSS overestimates nocturia in most patients.
The analysis of the patient’s voiding diary revealed a
night-time urine output of 800–950 ml and a 24-hour
urine output of 2,600–2,900 ml. Therefore, an adjustment
of fluid intake was advised. The clinical picture led to the
prescription of a combination treatment of tamsulosin 0.4mg
plus fesoterodine 4 mg, and the patient agreed to enroll in a
telephone and ambulatory clinic follow-up program.
One point of concern was nocturia. Weiss et al.
[18] showed that significant improvements were observed
with fesoterodine compared to placebo in the number of
micturition-related nocturnal urgency episodes (–1.28 versus
–1.07, p = 0.003), in the number of nocturnal micturitions per
24 hours (–1.02 versus –0.85, p = 0.011), and in the nocturnal
frequency urgency sum, defined as the sum of Urinary
Sensation Scale (USS) ratings recorded for all nocturnal
micturitions (–4.01 versus –3.42, p < 0.003). Additionally,
HRQoL measures were improved with fesoterodine.
A further six weeks later, the patient came back with
no change in nocturia, a slight improvement in urgency,
and complained of minimal dry mouth. Consequently, the
fesoterodine dose was increased to 8 mg per day and the
patient was kept in the follow-up study. His IPSS improved
to 10 and his QoL score on the IPSS improved to 2.
2.1. Discussion. This interesting case highlights important
clinical aspects leading to useful conclusions:
(i) The patient related his symptoms to BPH and was
at the beginning treated as a BPH patient only.
However, as storage symptoms and nocturia were also
present, the patient needed a customized (nonfixed)
combination.
(ii) In clinical studies, fesoterodine has demonstrated
efficacy on nocturia unrelated to nocturnal polyuria;
nocturnal polyuria should be managed by reducing
the urine output at night.
(iii) Urgency was actually the major cause of the QoL
deterioration but was treated last.
(iv) An appropriate follow-up programkept the patient on
treatment.
3. Second Case: Mrs. Young OAB
The second case refers to a 48-year-old woman, a busy
manager with a history of depression and sleep disturbance.
She has had three terminations of pregnancy and one
delivery by cesarean section. She smokes approximately ten
cigarettes per day and has high cholesterol serum levels.
She takes several medications: a selective serotonin reuptake
inhibitor (escitalopram), two benzodiazepines (delorazepam
and clonazepam), and a statin. She reports a four-year
history of urinary symptoms: daily UUI episodes, mild stress
urinary incontinence (SUI), and two episodes of nocturia per
night. She wears pads every day. The urology consultation
revealed some degree of pelvic pain, especially during vaginal
examination. The urine dipstick was negative and there
was no PVR. No specific causes of the symptoms such
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Table 1: Percentage decrease in urinary urgency incontinence and urgency episodes according to different studies with fesoterodine at 4 and
8 mg.
UUI decrease (%) 4/8 mg Urgency episode decrease (%) 4/8 mg
Chapple, 2007 [13] 80.8/87.5 17.6/19.1
Chapple, 2014 [12] 74.4/79.5 37.8/45.5
Kaplan, 2010 [14] 75.0 43.3
Dubeau, 2014 [15] 69.3 41.5
as urine tract infection were identified. The patient also
complained ofmild dyspareunia and occasional constipation.
The urine culture turned out to be sterile, with no blood
in urine, and the pelvic ultrasound scan and urine cytology
were also negative. The cystoscopy, which was performed
as a result of the presence of storage symptoms and to
rule out a bladder tumor in this current smoker, was nor-
mal.
In OAB patients, it is of utmost importance to consider
all comorbidities. Anxiety and depression may play a role,
feeding a vicious circle. Moreover, medications to treat neu-
rological or psychiatric disorders can influence OAB and be
responsible for side effects [19, 20]. Gastrointestinal disorders
are frequently associated with OAB, such as constipation in
this case, but patients rarely raise the topic. An overlap exists
between irritable bowel syndrome and OAB [21].
The patient was prescribed a 𝛽3 agonist, pelvic floor
muscle training (PFMT) and bladder retraining. Fourmonths
later, she noticed some degree of improvement, but had
stopped the treatment as she felt that she had no time for
PFMT. She was not compliant with the bladder drill either,
and soon stopped the 𝛽3 agonist because she did not sense
any real improvement. She also felt that she did not have
the time to complete a bladder diary. She was prescribed
fesoterodine 8 mg for three months. In parallel, her general
practitioner asked for vaginal and urethral culture swabs,
whichwere negative. After threemonths, her urinary urgency
improved, but she said that the few remaining episodes of
urgency were “killing her life” and that she did not want
to be on pills for her whole life. Therefore, she refused to
continue the treatment and requested an “easy fix”. Her
reaction highlights the need for careful consideration of the
consequences of incontinence in terms of QoL. A publication
fromVaughan et al. [22] reported that OAB and incontinence
synergize to reduce QoL, especially in the domains of sleep,
elimination, usual activities, discomfort, distress, vitality, and
sexual activity.
Consistent efficacy on urgency symptoms with a sig-
nificant decrease in UUI and urgency episodes has been
reported with fesoterodine at doses of 4 and 8 mg compared
to placebo (Table 1) [12, 13, 23, 24]; however, some patients
may react differently. Patient satisfaction is an important
driver of treatment success [14]. Patient expectations should
be considered carefully in the context of OAB management.
The achievement of patients’ goals was measured in the Study
Assessing FlexIble-dose fesoterodiNe in Adults (SAFINA
study) [15], a 12-week multicenter open label study with 331
OAB adults, using the Self-Assessment Goal Achievement
(SAGA) questionnaire. Fesoterodine treatment resulted in
81.3% of patients declaring that their goals were “some-
what achieved/achieved” or that the result “exceeded/greatly
exceeded their expectation”.
Our case patient had very specific expectations; she
refused to have an implant (neuromodulation), saying “I’m
not going to be an android!” She accepted botox injections,
and so a first set of injections was performed under local
anesthesia. She found the injections “a little painful” and “a
big annoyance”, but at the one-month follow-up visit after
botox injection she reported no more UUI episodes and
an improvement in frequency and the number of urgency
episodes, as well as in QoL. Even though she stated that she
did not like the idea of being a patient for the rest of her life,
she accepted subsequent injections.
3.1. Discussion. The clinical points that can be learned from
this case are as follows:
(i) AllOAB cases are different, and a thorough evaluation
is mandatory to adequately address each case.
(ii) It is important to assess other aspects, such as func-
tional and psychological disorders that may influence
symptoms, and to consider nonneurogenic OAB as a
multifactorial disease.
(iii) The major goal of initial therapy is to meet the
patient’s expectations regarding the reason for their
visit, to improve their satisfaction, and their QoL.
(iv) Due to fesoterodine’s characteristics and flexible
dosage, improvement of symptoms and achievement
of the patients’ goal are usually high with this medi-
cation.
(v) When patients have specific requirements, all options
should be discussed and the patient’s agreement
obtained.
(vi) A customized approach is a crucial factor for treat-
ment success.
(vii) OAB management should be personalized; beware of
a simplistic application of a standardized treatment
algorithm.
4. Third Case: Mrs. Mixed
Urinary Incontinence
The third case concerns a 73-year-old retired schoolteacher
who had had two children, born by forceps-assisted vaginal
delivery. She complained of ten episodes of daytime fre-
quency with small frequent voids, a constant desire to void,
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and three nocturia episodes per night, resulting in poor sleep.
More recently, things had deteriorated with a sudden urge
to void and occasional urinary incontinence with exercise.
She changed pads three times a day and complained of
superficial dyspareunia. She took medication (doxazosin and
furosemide) for well-controlled hypertension but did not
take hormone replacement therapy. She complained of mild
constipation and had had three lower urinary tract infections
(UTIs) in the last 12 months. During her consultation with
her general practitioner, she emphasized that urgency was
the most important problem for her. She was referred to
a gynecologist, who confirmed a subjective diagnosis of
mixed urinary incontinence with superficial dyspareunia
and vulval discomfort. The physical examination detected
a marked urogenital atrophy, a grade I uterine prolapse, a
grade I cystocele, and grade I rectocele. She was initially
prescribed vaginal estrogen, as supported by evidence from
Cochrane reviews [25, 26], and referral to a urogynecologist
was considered.
The urogynecologist confirmed the mixed urinary symp-
toms with urgency and UUI, SUI, recurrent UTIs, and mild
constipation. The clinical examination also confirmed uro-
genital atrophy, demonstrable SUI, and a urogenital prolapse
without evidence of neuropathy or specific etiology of the
symptoms.
The PVR was found to be 95 ml, urinalysis was negative,
and flexible cystoscopy was normal. The patient noticed an
improvement of vulval discomfort and dyspareuniawith local
estrogen therapy. The physician provided lifestyle advice,
prescribed PFMT training and oxybutynin 5 mg three times
a day, and undertook a medication review. The alpha blocker
doxazosin, which may aggravate the symptoms of SUI, was
switched to an angiotensin II receptor antagonist, losartan,
and furosemide was discontinued. The International Con-
sultation on Incontinence Modular Questionnaire (ICIQ)
and a bladder diary were completed. They showed that the
patient leaked a moderate amount of urine several times
a day, generating moderate bother. Incontinence occurred
before she could get to the toilet and was also associated
with exercise, coughing, and sneezing. She complained of
ten frequency episodes per day, three nocturia episodes with
moderate bother, and had a total VV at 2,190 ml. The night
volume was 490 ml, with no evidence of nocturnal polyuria.
This led to the symptomatic diagnosis of mixed incontinence,
which is an important common symptom and is particularly
difficult to treat. It has been defined by Haylen et al. [27] as
being “the complaint of involuntary loss of urine associated
with urgency and also with effort or physical exertion or on
sneezing or coughing”.
After six weeks, the patient returned and reported that
she had taken oxybutynin for six weeks and then stopped
due to persistent dry mouth and worsening constipation. She
had also performed bladder retraining and PFMT for two
weeks and then stopped. She noticed a mild improvement in
urgency andUUI, but no change in nocturia, and her SUI was
still troublesome.Theurogynecologist suggested switching to
fesoterodine 4 mg once a day and explained that she could
increase the dose if required [13, 28, 29].
What are the reasons to consider using fesoterodine, here
as a second line therapy, in a 73-year-old elderly woman?
Fesoterodine is the only OAB medication classified as B
(Beneficial) by the Fit fOR The Aged (FORTA) classification
[30]. LUTS-FORTA results from a systematic review of drugs
treating LUTS in the elderly in order to evaluate their efficacy,
safety, and tolerability. Darifenacin, mirabegron, oxybutynin
ER, solifenacin, tolterodine, and trospium were classified as
FORTA C (Questionable; Caution), while oxybutynin IR and
propiverine were classified as FORTA D (Avoid; Do not).
This classification suggests that fesoterodine may have better
efficacy and tolerability in elderly patients.
Moreover, the combination of fesoterodine with vaginal
estrogen may act synergistically. Chugtai et al. [31] have
studied the results of combining fesoterodine with vagi-
nal estrogen and showed that this combination improved
OAB symptoms and sexual function in postmenopausal
women, and importantly, produced greater improvement in
QoL.
At 12 weeks the urogynecologist reviewed her clinical
picture. Fesoterodine 4 mg was well tolerated and there
was no need for a dose increase, her urgency and urgency
incontinence symptoms were improved, and the number
of voids per day had decreased to seven, but remained at
two per night. Her symptoms of urogenital atrophy and
dyspareunia had improved and there was no reported UTI.
Constipation improved with dietary advice and possibly by
stopping oxybutynin as well. While her urogenital prolapse
remained asymptomatic, her SUI remained troublesome.
With regard to adverse effects, the fact that patients cope
better with dry mouth with fesoterodine compared to oxy-
butynin may lie in the selectivity of 5-HMT for the bladder
over the salivary glands. An in vitro and in vivo study, using
radioligand binding, has demonstrated that oxybutynin has
a threefold higher affinity for the salivary glands over the
bladder [32] and therefore has a greater propensity to induce
dry mouth.
At the 24-week visit, the urogynecologist’s review was
in favor of continuing with fesoterodine 4 mg since the
patient’s urgency and UUI were much improved. However,
there was still some SUI limiting her physical activity. The
urodynamic investigations performed while the patient was
on fesoterodine showed a cystometric capacity of 500 ml,
no evidence of detrusor overactivity, moderate urodynamic
SUI, and no evidence of voiding dysfunction. Hence, as
suggested by the 6th International Consultation on Inconti-
nence [33], the urogynecologist discussed the possibility of
surgery for SUI and continued the current pharmacological
treatment.
4.1. Discussion. This clinical case illustrates some important
take-home messages:
(i) It is important to treat the most bothersome symp-
toms first.
(ii) In case of mixed urinary symptoms, there is a need to
look for a possible urogenital prolapse; this particular
patient had demonstrable genital prolapse but did not
find it troublesome.
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(iii) Fesoterodine is effective and well tolerated in the
elderly, and is rated B (beneficial) by the LUTS-
FORTA classification.
(iv) Vaginal estrogen is effective in the management of
urogenital atrophy and recurrent UTIs.
(v) There is evidence to support the combined use of
estrogen and antimuscarinics.
(vi) Nocturia secondary to nocturnal polyuria does not
respond to antimuscarinic medication and should
benefit from lifestyle advice and consideration of
desmopressin treatment.
Finally, the conclusions were that, firstly, the cornerstone
symptom of OAB, urgency, is very common, and that many
OAB patients may not be diagnosed appropriately. Secondly,
whenurgency is diagnosed, the use of antimuscarinics should
be considered.Thirdly, fesoterodine has the benefit of flexible
dosing and can be titrated accordingly; therefore, before
switching to another medication, increasing the dose for fur-
ther efficacy should be considered. Finally, the patient should
not be considered as a passive subject but as a real actor in
the treatment process; involving her/him in the treatment
plan increases her/his adherence and the improvement of
treatment outcomes.
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